XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · Real-Time Price · USD
2.020
+0.050 (2.54%)
At close: Oct 23, 2026, 4:00 PM EDT
1.760
-0.260 (-12.87%)
After-hours: Oct 23, 2026, 6:38 PM EDT
Company Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel.
The company’s lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome.
It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.
XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
XTL Biopharmaceuticals Ltd.
| Country | Israel |
| Founded | 1993 |
| IPO Date | Sep 1, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Noam Band |
Contact Details
Address: 85 Medinat Hayehudim St. Herzliya, 4676670 Israel | |
| Phone | 972 5 4228 8897 |
| Website | xtlbio.com |
Stock Details
| Ticker Symbol | XTLB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001023549 |
| CUSIP Number | 98386D406 |
| ISIN Number | US98386D4060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Noam Band | Chief Executive Officer and Director |
| Segal Niv CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 14, 2026 | 6-K | Report of foreign issuer |
| Aug 5, 2026 | 6-K | Report of foreign issuer |
| Jul 21, 2026 | 6-K | Report of foreign issuer |
| Jun 30, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Jun 30, 2026 | 6-K | Report of foreign issuer |
| Jun 29, 2026 | 6-K | Report of foreign issuer |
| Jun 23, 2026 | 6-K | Report of foreign issuer |
| May 22, 2026 | 6-K | Report of foreign issuer |
| May 15, 2026 | 6-K | Report of foreign issuer |
| May 7, 2026 | 6-K | Report of foreign issuer |